Citigroup Inc. Sells 70,631 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Citigroup Inc. reduced its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRSGet Rating) by 8.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 767,084 shares of the biotechnology company’s stock after selling 70,631 shares during the quarter. Citigroup Inc. owned about 0.99% of Coherus BioSciences worth $6,075,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Captrust Financial Advisors increased its stake in Coherus BioSciences by 1,461.0% during the first quarter. Captrust Financial Advisors now owns 2,404 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 2,250 shares during the last quarter. Eagle Bay Advisors LLC boosted its position in shares of Coherus BioSciences by 136.1% during the second quarter. Eagle Bay Advisors LLC now owns 3,891 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 2,243 shares during the period. Federated Hermes Inc. boosted its position in shares of Coherus BioSciences by 55.0% during the third quarter. Federated Hermes Inc. now owns 4,223 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 1,498 shares during the period. Verition Fund Management LLC purchased a new position in shares of Coherus BioSciences during the third quarter valued at approximately $103,000. Finally, Mutual of America Capital Management LLC boosted its position in shares of Coherus BioSciences by 18.9% during the third quarter. Mutual of America Capital Management LLC now owns 12,835 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 2,042 shares during the period. 99.45% of the stock is owned by institutional investors.

Coherus BioSciences Trading Up 0.7 %

Shares of CHRS stock opened at $4.54 on Friday. The business’s fifty day simple moving average is $6.82 and its 200-day simple moving average is $7.42. The company has a market cap of $365.70 million, a PE ratio of -1.30 and a beta of 0.95. Coherus BioSciences, Inc. has a 12-month low of $4.39 and a 12-month high of $14.11.

Coherus BioSciences (NASDAQ:CHRSGet Rating) last issued its quarterly earnings results on Monday, March 6th. The biotechnology company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.12). The firm had revenue of $45.35 million during the quarter, compared to analyst estimates of $45.72 million. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. On average, equities analysts forecast that Coherus BioSciences, Inc. will post -2.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on CHRS shares. Maxim Group dropped their target price on Coherus BioSciences from $15.00 to $12.00 in a research report on Friday, May 12th. StockNews.com initiated coverage on Coherus BioSciences in a research report on Thursday. They set a “hold” rating for the company. Barclays lowered their price target on Coherus BioSciences from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, March 8th. Truist Financial initiated coverage on Coherus BioSciences in a report on Monday, May 1st. They issued a “buy” rating and a $24.00 price target for the company. Finally, HC Wainwright lowered their price target on Coherus BioSciences from $26.00 to $24.00 in a report on Tuesday, May 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.86.

Coherus BioSciences Profile

(Get Rating)

Coherus BioSciences, Inc is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Read More

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.